Development and validation of a genomic mutation signature to predict response to PD-1 inhibitors in non-squamous NSCLC: a multicohort study

Xue Bai(Northwest University), Zhong‐Yi Dong(Southern Medical University), Shuai Kang(Shenyang Institute of Automation), Qiang Fu(Saint Louis University), Dehua Wu(Nanfang Hospital), Hongbo Zhu(Fudan University), Si-Cong Ma(Nanfang Hospital), Jian Wang(Shandong Provincial Hospital), Yi‐Long Wu(Guangdong General Hospital), Yuhan Chen(Sun Yat-sen University), He-San Luo(Nanfang Hospital), Hong‐Hong Yan(Sun Yat-sen University), Chuanhui Cao(Ganzhou People's Hospital), Xin-Ran Tang(Nanfang Hospital)
Journal for ImmunoTherapy of Cancer
June 1, 2020
10.1136/jitc-2019-000381
Cited by 63

Related Papers

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
|New England Journal of Medicine|2009|8.2k
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2019|3.3k
Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer
|New England Journal of Medicine|2016|3.3k